HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Multicentre phase II study of CyclOBEAP plus rituximab in patients with diffuse large B-cell lymphoma.

Abstract
The R-CHOP regimen has been found to improve the outcome of diffuse large B-cell lymphoma (DLBCL). However, it does not provide a satisfactory treatment outcome in the high-risk group. We previously administered the CyclOBEAP regimen to patients with DLBCL, and reported its safety and efficacy. The R-CyclOBEAP regimen was administered over a total period of 12 weeks, and rituximab 375 mg/m(2) was given every 2 weeks. There were 101 eligible patients. CR was achieved in 96 patients (95%). The 5-year overall survival (OS) rate was 85% and progression-free survival (PFS) rate was 76%. When the patients were divided according to the IPI, the 5-year OS and PFS rates did not significantly differ among the risk groups. The 5-year PFS of the germinal centre B-cell group was 80% and that of the non-GCB group was 74% (NS). Univariate analysis showed that the presence of B symptoms, extranodal lesions >or=2, and sIL-2R were significant poor prognostic factors. Grade 4 neutropenia was observed in 91 patients and thrombocytopenia in 9 patients. The addition of rituximab to CyclOBEAP therapy may enhance the effect of CyclOBEAP therapy for DLBCL.
AuthorsNozomi Niitsu, Mika Kohri, Yuki Hagiwara, Ken Tanae, Naoki Takahashi, Masami Bessho, Masataka Okamoto
JournalHematological oncology (Hematol Oncol) Vol. 28 Issue 2 Pg. 68-74 (Jun 2010) ISSN: 1099-1069 [Electronic] England
PMID20235332 (Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study)
Copyright(c) 2010 John Wiley & Sons, Ltd.
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Bleomycin
  • Rituximab
  • Vincristine
  • Etoposide
  • Doxorubicin
  • Cyclophosphamide
  • Prednisolone
Topics
  • Adult
  • Antibodies, Monoclonal (administration & dosage, adverse effects)
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects, therapeutic use)
  • Bleomycin (administration & dosage, adverse effects)
  • Cyclophosphamide (administration & dosage, adverse effects)
  • Disease-Free Survival
  • Doxorubicin (administration & dosage, adverse effects)
  • Drug Administration Schedule
  • Etoposide (administration & dosage, adverse effects)
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Lymphoma, Large B-Cell, Diffuse (drug therapy)
  • Male
  • Middle Aged
  • Neutropenia (chemically induced)
  • Prednisolone (administration & dosage, adverse effects)
  • Prognosis
  • Rituximab
  • Thrombocytopenia (chemically induced)
  • Treatment Outcome
  • Vincristine (administration & dosage, adverse effects)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: